Anticoagulant action of sugammadex
Conditions
Interventions
Pyridostigmine 0.15 mg/kg plus glycopyrrolated administered atthe end of surgery.
Sugammadex 4mg/kg, administered at the end of surgery
Sponsors
Korea University Guro Hospital Department of Anesthesiology and Pain Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: American society of Anesthesiologists physical class 1-2, presenting for elective surgery (gynaecological, urologic, and colorectal surgery) were enrolled.
Exclusion criteria
Exclusion criteria: Patients were excluded from study if they have neuromuscular disease, hereditary coagulation defect, renal or hepatic dysfunction, known allergy to sugammadex, recent history of hemorrhage or thrombosis within 30 days, difficult airway features, abnormal coagulation laboratory value (e.g., prothrombin time internalization normalized ratio >1.5, activated partial thromboplastin time > 50 sec), or if they were pregnant or women who were breast feeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| reaction time (r) coagulation time (k) | — |
Secondary
| Measure | Time frame |
|---|---|
| Maximum rate of thrombus generation (MRTG) Time to maximum rate of thrombus generation (TMRTG) Maximum amplitude (MA) Angle alpha | — |
Countries
Asia(except Japan)
Contacts
Public ContactMido Lee
Korea University Guro Hospital Anesthesiology and Pain Medicine
Outcome results
None listed